KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Investment Income (2016 - 2017)

Supernus Pharmaceuticals (SUPN) has disclosed Non Operating Investment Income for 6 consecutive years, with $23000.0 as the latest value for Q2 2017.

  • On a quarterly basis, Non Operating Investment Income fell 81.3% to $23000.0 in Q2 2017 year-over-year; TTM through Dec 2017 was $77000.0, a 82.81% decrease, with the full-year FY2017 number at $76000.0, down 83.04% from a year prior.
  • Non Operating Investment Income was $23000.0 for Q2 2017 at Supernus Pharmaceuticals, down from $54000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $760000.0 in Q3 2014 to a low of -$8.6 million in Q2 2013.
  • A 5-year average of -$545888.9 and a median of $100000.0 in 2016 define the central range for Non Operating Investment Income.
  • Peak YoY movement for Non Operating Investment Income: tumbled 5885.42% in 2013, then surged 12200.0% in 2016.
  • Supernus Pharmaceuticals' Non Operating Investment Income stood at -$662000.0 in 2013, then skyrocketed by 204.83% to $694000.0 in 2014, then plummeted by 81.7% to $127000.0 in 2015, then fell by 22.05% to $99000.0 in 2016, then crashed by 76.77% to $23000.0 in 2017.
  • Per Business Quant, the three most recent readings for SUPN's Non Operating Investment Income are $23000.0 (Q2 2017), $54000.0 (Q1 2017), and $99000.0 (Q4 2016).